Revenue distribution by industry:

• Biopharmaceuticals: 70%
• Generics: 20%
• Research and Development: 10%

TOP 3 markets and their percentage shares:

• China: 65%
• USA: 20%
• Europe: 10%

3SBio Inc. generates the majority of its revenue from the biopharmaceutical industry, which is attributed to its specialization in the development and marketing of biological drugs. The Chinese market is the largest single market for the company, supported by a strong presence and growing demand for biopharmaceutical products in the region.

The U.S. market follows in second place, with the company benefiting from high demand for innovative therapies. Europe represents the third largest market, with a growing interest in 3SBio's products in this region as well.

Production Sites: Shenyang, China

3SBio Inc. mainly produces its products in Shenyang, China. The company has modern production facilities there that meet international standards. This strategic location enables 3SBio to efficiently serve both the domestic and international markets.

Focus on Biopharmaceutical Innovations: 3SBio Inc. is heavily investing in research and development to develop innovative biopharmaceutical products.

Expansion of Product Pipeline: The company plans to expand its product pipeline through strategic partnerships and acquisitions.

International Expansion: 3SBio Inc. aims to increase its presence in international markets, particularly in the USA and Europe.

3SBio Inc. pursues a growth strategy based on the development of new biopharmaceutical products. Through significant investments in research and development, the company aims to strengthen its position as a leading provider of biopharmaceutical solutions.

In addition, 3SBio is relying on strategic partnerships and acquisitions to expand its product pipeline and tap into new markets. Another focus is on international expansion, particularly in the USA and Europe, to promote global growth.

Imported Raw Materials/Ingredients: Biopharmaceutical active ingredients, packaging materials

Countries of Origin: USA, Germany, China

3SBio Inc. is a leading biopharmaceutical company specializing in the development, manufacturing, and marketing of biopharmaceutical products. For the production of their medications, the company imports biopharmaceutical active ingredients necessary for the manufacturing of biologics. These ingredients are often sourced from countries such as the USA and Germany, known for their advanced biotechnological research and production.

Additionally, 3SBio imports packaging materials required for the safe transport and storage of their products. These materials often come from China, which plays a significant role in the global supply chain for packaging materials. The combination of these raw materials and materials enables 3SBio to produce and market high-quality biopharmaceutical products.

Market share in China: 8.5% (2024, estimate)
R&D investments: 12% of revenue (2024)
Product diversification: Over 20 approved products

3SBio Inc. has a solid competitive advantage in the Chinese biopharma market, especially through its strong presence in oncology and autoimmune diseases. The company continuously invests in research and development, enabling it to bring innovative products to market and expand existing product lines.

The competitive advantage is reinforced by a wide range of products and strategic partnerships both domestically and internationally. This diversification and the ability to rapidly develop and market new products help solidify 3SBio's market position.

Additionally, 3SBio benefits from a strong infrastructure in China, allowing it to operate efficiently and respond quickly to market changes. The ongoing investments in R&D and strategic expansion into international markets strengthen the company's long-term competitive advantage.

Institutional Investor Share: approximately 45% (2025, estimated)

Insider Purchases/Sales: No significant transactions in the last year (2025, estimated)

The institutional investor share in 3SBio Inc. is around 45%, indicating a strong interest from institutional investors. These investors typically value the company's stability and growth potential.

In 2025, there were no significant insider purchases or sales, suggesting that the company's executives and insiders do not anticipate any major changes in the company's valuation or strategy at present. This can be seen as a sign of stability and confidence in the company's future development.

Market share of 3SBio Inc.: 4.5% (2025, estimated)
Top competitors and their market shares:

1. Roche Holding AG: 15%
2. Amgen Inc.: 12%
3. Johnson & Johnson: 10%
4. Pfizer Inc.: 9%
5. Sanofi: 8%
6. Novartis AG: 7%
7. 3SBio Inc.: 4.5%
8. Biogen Inc.: 4%
9. Bayer AG: 3.5%
10. AstraZeneca: 3%

3SBio Inc. has a moderate market share compared to the industry's leading companies. The main advantage of 3SBio lies in its specialization in biopharmaceutical products, particularly in oncology and nephrology, as well as its strong presence in the Chinese market. This specialization and geographical focus can be seen as a certain moat.

However, compared to larger competitors like Roche or Amgen, which have a broader product portfolio and a stronger global presence, 3SBio has a less pronounced moat. The larger companies benefit from more extensive research and development budgets, established brands, and global distribution networks that give them a significant competitive advantage.

Overall, 3SBio has a certain strategic advantage in niche markets and in the domestic market, but the moat is less pronounced compared to the leading global companies.

Revenue Growth: 10% (2024) Research and Development Expense: 20% of revenue (2024) Market Share in the Biopharma Sector in China: 5% (2024)

3SBio Inc. recorded a revenue growth of 10% in 2024, attributed to the successful launch of new products and expansion into international markets. The company continues to heavily invest in research and development, with an expense of 20% of revenue, indicating a strategic focus on innovation and long-term growth.

3SBio's market share in the Chinese biopharma sector is approximately 5%, representing a strong position in one of the world's largest and fastest-growing pharmaceutical markets. The ongoing focus on innovative therapies and the exploration of new markets could further increase growth potential.

Overall, the strong R&D investment and solid market position suggest that 3SBio Inc. could be an attractive investment opportunity for long-term investors interested in the developments in the biopharma sector.

Dividend Yield: 2.5% (estimated for 2025)
Dividend History: Regular payout since 2020

3SBio Inc. has distributed dividends in recent years, with the dividend yield estimated to be around 2.5% for 2025. The company has been paying dividends regularly since 2020, indicating a certain reliability in its payouts.

The reliability of the dividend depends on the financial stability and future earnings of the company. 3SBio Inc. has historically generated stable revenue from its biopharmaceutical products, supporting a continuous dividend payment. However, analysts recommend monitoring future business developments and cash flow to assess the sustainability of dividend payments.